Ragweed sublingual tablet immunotherapy: Part II - Practical considerations and pertinent issues

Research output: Contribution to journalArticle

Abstract

Sublingual allergen immunotherapy (SLIT) has been demonstrated to be both efficacious and safe for the treatment of respiratory allergies such as allergic rhinoconjunctivitis or allergic asthma. Based on the clinical documentation of SLIT ragweed tablets, they have gained marketing authorization in the USA by the US FDA in 2014 for adult patients. Following clinical data from (pivotal) multicenter Phase II and III trials as performed in the USA and Canada and real life experience after registration in 2014, SLIT ragweed tablets can be recommended as efficacious and safe treatment option with disease modifying potential when adequately indicated and performed. Therefore, several practical issues should be considered for treating ragweed allergic patients with these tablets. This second part of a thorough review on ragweed SLIT tablets addresses important clinical questions which should be taken into account by the subscribing practitioner before initiation and during the treatment.

Original languageEnglish (US)
Pages (from-to)617-626
Number of pages10
JournalImmunotherapy
Volume10
Issue number7
DOIs
StatePublished - Jun 1 2018

Fingerprint

Sublingual Immunotherapy
Immunologic Desensitization
Ambrosia
Tablets
Life Change Events
Marketing
Documentation
Canada
Hypersensitivity
Therapeutics
Asthma

Keywords

  • allergen immunotherapy
  • practical considerations
  • ragweed
  • SLIT
  • tablet

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Ragweed sublingual tablet immunotherapy : Part II - Practical considerations and pertinent issues. / Pfaar, Oliver; Creticos, Peter Socrates.

In: Immunotherapy, Vol. 10, No. 7, 01.06.2018, p. 617-626.

Research output: Contribution to journalArticle

@article{7ea9bcdeb2d54f6b86a6fbb46c9feb65,
title = "Ragweed sublingual tablet immunotherapy: Part II - Practical considerations and pertinent issues",
abstract = "Sublingual allergen immunotherapy (SLIT) has been demonstrated to be both efficacious and safe for the treatment of respiratory allergies such as allergic rhinoconjunctivitis or allergic asthma. Based on the clinical documentation of SLIT ragweed tablets, they have gained marketing authorization in the USA by the US FDA in 2014 for adult patients. Following clinical data from (pivotal) multicenter Phase II and III trials as performed in the USA and Canada and real life experience after registration in 2014, SLIT ragweed tablets can be recommended as efficacious and safe treatment option with disease modifying potential when adequately indicated and performed. Therefore, several practical issues should be considered for treating ragweed allergic patients with these tablets. This second part of a thorough review on ragweed SLIT tablets addresses important clinical questions which should be taken into account by the subscribing practitioner before initiation and during the treatment.",
keywords = "allergen immunotherapy, practical considerations, ragweed, SLIT, tablet",
author = "Oliver Pfaar and Creticos, {Peter Socrates}",
year = "2018",
month = "6",
day = "1",
doi = "10.2217/imt-2018-0003",
language = "English (US)",
volume = "10",
pages = "617--626",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "7",

}

TY - JOUR

T1 - Ragweed sublingual tablet immunotherapy

T2 - Part II - Practical considerations and pertinent issues

AU - Pfaar, Oliver

AU - Creticos, Peter Socrates

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Sublingual allergen immunotherapy (SLIT) has been demonstrated to be both efficacious and safe for the treatment of respiratory allergies such as allergic rhinoconjunctivitis or allergic asthma. Based on the clinical documentation of SLIT ragweed tablets, they have gained marketing authorization in the USA by the US FDA in 2014 for adult patients. Following clinical data from (pivotal) multicenter Phase II and III trials as performed in the USA and Canada and real life experience after registration in 2014, SLIT ragweed tablets can be recommended as efficacious and safe treatment option with disease modifying potential when adequately indicated and performed. Therefore, several practical issues should be considered for treating ragweed allergic patients with these tablets. This second part of a thorough review on ragweed SLIT tablets addresses important clinical questions which should be taken into account by the subscribing practitioner before initiation and during the treatment.

AB - Sublingual allergen immunotherapy (SLIT) has been demonstrated to be both efficacious and safe for the treatment of respiratory allergies such as allergic rhinoconjunctivitis or allergic asthma. Based on the clinical documentation of SLIT ragweed tablets, they have gained marketing authorization in the USA by the US FDA in 2014 for adult patients. Following clinical data from (pivotal) multicenter Phase II and III trials as performed in the USA and Canada and real life experience after registration in 2014, SLIT ragweed tablets can be recommended as efficacious and safe treatment option with disease modifying potential when adequately indicated and performed. Therefore, several practical issues should be considered for treating ragweed allergic patients with these tablets. This second part of a thorough review on ragweed SLIT tablets addresses important clinical questions which should be taken into account by the subscribing practitioner before initiation and during the treatment.

KW - allergen immunotherapy

KW - practical considerations

KW - ragweed

KW - SLIT

KW - tablet

UR - http://www.scopus.com/inward/record.url?scp=85047860794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047860794&partnerID=8YFLogxK

U2 - 10.2217/imt-2018-0003

DO - 10.2217/imt-2018-0003

M3 - Article

C2 - 29764261

AN - SCOPUS:85047860794

VL - 10

SP - 617

EP - 626

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 7

ER -